Sangamo Biosciences (SGMO) Misses Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall Street ends choppy session lower as tech shares drop
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
Sangamo BioSciences Reports Second Quarter 2016 Financial Results
August 3, 2016 4:03 PM EDTRICHMOND, Calif., Aug. 3, 2016 /PRNewswire/ --Â Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its second quarter 2016 financial results and updated on recent events and development timelines for its preclinical and clinical therapeutic programs.
"My mandate as CEO of Sangamo is to lead the Company in its transition from a research-focused... More
